Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2023-02-28 Annual Report
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2022
2023-02-28 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release with financial results for the fourth quarter and year ended December 31, 2022. However, the actual financial results are contained in an attached press release (Exhibit 99.1) and not in the 8-K text itself. The 8-K states that the information is "being furnished and shall not be deemed 'filed'" and is incorporated by reference, indicating this document is primarily an announcement of financial results rather than the full earnings release itself. The document length is 3831 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "MENU VS MEAL" rule, since this document is short and references an attached press release for the financial results, it should be classified as an Earnings Release (ER) because Form 8-K Item 2.02 is commonly used to announce earnings releases. The document is not a full transcript, annual report, or other detailed report, but an initial announcement of quarterly/year-end financial results. Therefore, the best classification is Earnings Release (ER) with high confidence.
2023-02-28 English
PRIMARY DOCUMENT
Director's Dealing
2023-02-14 English
SC 13G
Major Shareholding Notification
2023-02-13 English
SC 13G/A
Major Shareholding Notification
2023-02-13 English
SCHEDULE 13G
Major Shareholding Notification
2023-02-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.